Video

Dr. Ornstein on Unmet Needs in Refractory RCC

Moshe Ornstein, MD, MA, discusses unmet needs in metastatic renal cell carcinoma.

Moshe Ornstein, MD, MA, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses unmet needs in metastatic renal cell carcinoma (mRCC).

Although there has been much progress over the past 5 to 10 years in the treatment of patients with metastatic kidney cancer, there are remaining questions that the field must address with future research and clinical trials, Ornstein says. Much of the progress has been in treatment-naïve mRCC, but how to manage those patients after their cancer progresses on front-line therapies remains a challenge, Ornstein explains.

Many of the agents that are available for refractory RCC have response rates between 20% and 30% and poor progression-free survival, Ornstein continues. Overall, trials are aiming to discover a therapy that can produce durable benefit in patients with refractory RCC, Ornstein concludes.

Related Videos
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center